3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
3
Terminated
2
Unknown
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
46
Gynecologic
12
CNS
8
Tumor-Agnostic
5
Sarcoma
4
Other solid neoplasm
2
Genitourinary
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
Cisplatin
99
pembrolizumab
81
Radiotherapy
51
Carboplatin
42
Radiotherapy, Intensity-Modulated
36
Magnetic Resonance Spectroscopy
36
toripalimab
33
Gemcitabine
29
Docetaxel
28
Cetuximab
28
Specimen Handling
25
Surgical Procedures, Operative
23
Paclitaxel
23
Fluorouracil
22
Radiation
20
Nivolumab
20
Blood Specimen Collection
19
Drug Therapy
18
Biopsy
18
Chemoradiotherapy
17
Surveys and Questionnaires
14
Standard of Care
14
Capecitabine
14
tislelizumab
13
Platinum
13
camrelizumab
12
nimotuzumab
11
130-nm albumin-bound paclitaxel
11
1,2-diaminocyclohexaneplatinum II citrate
11
cemiplimab
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
abemaciclib
×
Head & Neck
×
Clear all
NCT05768139
2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled